相关实验视频

Updated: Jan 13, 2026

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

L-FABP作为肝移植损伤的潜在生物分子标记物

Ana Kalamutova^1,2, Danaja Plevel^1,2, Mihajlo Djokic^1,2

¹Department of Abdominal Surgery, University Medical Centre Ljubljana, Zaloska 7, 1000 Ljubljana, Slovenia.

Journal of clinical medicine

|October 29, 2025

概括

肝类型脂肪酸结合蛋白 (L-FABP) 可能在移植受体中检测到早期的肝移植损伤,特别是来自老年捐赠者的肝移植损伤. 这种生物标志物显示出超越标准肝功能测试的前景.

科学领域:

移植免疫学移植免疫学
肝病学肝病学是一种肝病学.
发现生物标志物的发现.

背景情况:

肝移植的指示和接受者的年龄正在增加.
移植后的并发症往往伴有非特异性症状.
新型生物标志物对于评估移植品质和早期发现并发症至关重要.

研究的目的:

研究肝型脂肪酸结合蛋白 (L-FABP) 作为亚临床肝移植损伤的生物标志物的潜力.
为了将L-FABP水平与供体年龄和移植后并发症相关联.

主要方法:

对29名成年肝移植接受者的前性单中心研究.
血清L-FABP测量在手术前和手术后的1,3,5,7和14天.
使用非参数测试分析临床,外科和生化数据.

主要成果:

在65岁以上的捐赠者移植的接受者中,在术后第7天的L-FABP显著更高 (p = 0.035).
对于感染性并发症的L-FABP没有显著差异 (p > 0.05).
在POD 5 (ρ = -0.677) 和POD 7 (ρ = -0.455) 中,手术内输血量和L-FABP之间存在强烈的负相关性.

结论:

L-FABP显示了潜在的早期检测亚临床肝移植细胞损伤.
与传统的肝功能生物标志物相比,L-FABP可能具有优势.
需要进一步的研究来验证L-FABP在肝移植结果中的有效性.

关键词:

在 L-FABP 中,生物标志物生物标志物肝脏移植损伤肝脏移植损伤肝移植肝移植肝移植边缘性肝脏移植移植

更多相关视频

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

相关概念视频

Ultrasound II: Endoscopic Ultrasound and FibroScan

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...